Takeda Pharmaceutical will divest Takeda Consumer Healthcare Company Limited (TCHC) to The Blackstone Group for $2.3 billion as the company continues to divest non-core business units in order to pare down debt accumulated from its $62 billion acquisition of Shire Plc.

Sanofi is lining up to spin off the active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.

Johnson & Johnson will stop selling talc Baby Powder in the United States and Canada, saying demand had fallen in the wake of what the company called “misinformation” about the product’s safety amid a barrage of legal challenges.

Moon Rabbit, an independent advertising and marketing agency focused on the consumer and healthcare sectors, announced the expansion of the firm’s U.S. headquarters in New York. Twenty-five new team members joined the agency to serve Moon Rabbit’s growing client base, and the firm moved into an expanded space in SoHo.

GlaxoSmithKline outlined a plan to split the company into two entities over the next two years.

Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.

French drugs and healthcare group Sanofi signed a rights deal with Roche for Tamiflu in the United States.

GlaxoSmithKline offered concessions to address EU antitrust concerns over the planned joint venture with Pfizer’s consumer health business, the European Commission said.

Stada said on Friday the private equity-backed company would buy six consumer healthcare products from British GlaxoSmithKline to bolster the generic drugmaker’s presence in Europe.

Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.